



Commonwealth of Massachusetts
MassHealth Drug Utilization Review Program
 P.O. Box 2586, Worcester, MA 01613-2586
Fax: 1-877-208-7428 **Phone:** 1-800-745-7318

Immunomodulators Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at www.mass.gov/druglist.

Member information

Last name _____ First name _____ MI _____
 MassHealth member ID # _____ Date of birth _____
 Gender (Check one.) F M Member's place of residence home nursing facility

Medication information

Medication requested

- | | | |
|--|--|--|
| <input type="checkbox"/> Actemra (tocilizumab) | <input type="checkbox"/> Kineret (anakinra) | <input type="checkbox"/> Simponi Aria (golimumab for infusion) |
| <input type="checkbox"/> Cimzia (certolizumab) | <input type="checkbox"/> Olumiant (baricitinib) | <input type="checkbox"/> Stelara (ustekinumab) |
| <input type="checkbox"/> Cosentyx (secukinumab) | <input type="checkbox"/> Orencia (abatacept) | <input type="checkbox"/> Taltz (ixekizumab) |
| <input type="checkbox"/> Enbrel (etanercept) | <input type="checkbox"/> Otezla (apremilast) | <input type="checkbox"/> Tremfya (guselkumab) |
| <input type="checkbox"/> Entyvio (vedolizumab) | <input type="checkbox"/> Remicade (infliximab) | <input type="checkbox"/> Xeljanz (tofacitinib) |
| <input type="checkbox"/> Humira (adalimumab) | <input type="checkbox"/> Renflexis (infliximab-abda) | <input type="checkbox"/> Xeljanz XR (tofacitinib extended-release) |
| <input type="checkbox"/> Inflectra (infliximab-dyyb) | <input type="checkbox"/> Siliq (brodalumab) | |
| <input type="checkbox"/> Kevzara (sarilumab) | <input type="checkbox"/> Simponi (golimumab) | |

Dose, frequency, and duration of medication requested _____

Indication (Check all that apply.)

- | | |
|--|--|
| <input type="checkbox"/> Ankylosing spondylitis | <input type="checkbox"/> Plaque psoriasis |
| <input type="checkbox"/> Axial (spine) involvement | <input type="checkbox"/> Polyarticular juvenile idiopathic arthritis |
| <input type="checkbox"/> Crohn's disease | <input type="checkbox"/> Psoriatic arthritis |
| <input type="checkbox"/> Cytokine release syndrome | <input type="checkbox"/> Axial (spine) involvement |
| <input type="checkbox"/> Giant cell arteritis | <input type="checkbox"/> Rheumatoid arthritis |
| <input type="checkbox"/> Hidradenitis suppurativa (Hurley Stage II or III) | <input type="checkbox"/> Ulcerative colitis |
| <input type="checkbox"/> Non-infectious uveitis | <input type="checkbox"/> Other _____ |

Please specify severity of indication below.

- Mild Mild-moderate Moderate Moderate-severe Severe

Is the member stabilized on the requested medication? Yes. Please provide start date. _____ No.

Section I. Please complete for all requests. For a diagnosis of hidradenitis suppurativa (Hurley Stage II or III) or non-infectious uveitis, please complete questions 1 and 2. For all other diagnoses, please complete questions 1 through 3.

1. Member's current weight _____
2. Please indicate whether the request is for pharmacy or in-office billing. Pharmacy billing In-office billing
3. Has the member tried disease modifying antirheumatic drugs (DMARDs)?
 Yes. Please list the drug names, dates/duration of trials and outcomes in Section IX below.*
 No. Please explain why not. _____

Section II. Please also complete for treatment of plaque psoriasis with Cosentyx, Enbrel, Humira, Inflectra, Otezla, Remicade, Renflexis, Siliq, Stelara, Taltz, or Tremfya.

Has the member tried other therapies to treat this condition including topical agents, systemic agents, and phototherapy?

- Yes. Please list the names of the therapies, dates/duration of trials and outcomes in Section IX below.*
 No. Please explain why not. _____

Section III. Please also complete for treatment of Crohn's disease with Cimzia, Entyvio, Humira, Inflectra, Remicade, Renflexis, or Stelara.

1. Has the member tried other medications to treat this condition including aminosalicylate, antibiotic, corticosteroid, and an immunomodulator (e.g., azathioprine, 6-mercaptopurine, or methotrexate)?
 Yes. Please list the drug names, dates/duration of trials and outcomes in Section IX below.*
 No. Please explain why not. _____
2. If the request is for Cimzia, Entyvio, Humira, or Stelara for fistulizing Crohn's disease, has the member tried Inflectra, Remicade, or Renflexis?
 Yes. Please list the drug name, dates/duration of trial and outcomes in Section IX below.*
 No. Please explain why not. _____

Section IV. Please also complete for treatment of ulcerative colitis with Entyvio, Humira, Inflectra, Simponi, Remicade, Renflexis or Xeljanz.

Has the member tried other medications to treat this condition including aminosalicylate, corticosteroid, and an immunomodulator (e.g., azathioprine or 6-mercaptopurine)?

- Yes. Please list the drug name, dates/duration of trials and outcomes in Section IX below.*
 No. Please explain why not. _____

Section V. Please also complete for treatment of non-infectious uveitis with Humira and for treatment of giant cell arteritis with Actemra.

Has the member tried other medications to treat this condition including glucocorticoid and immunosuppressive therapy?

- Yes. Please list the drug name, dates/duration of trials and outcomes in Section IX below.*
 No. Please explain why not. _____

Section VI. Please also complete for Kineret requests.

Has the member tried an anti-tumor necrosis factor (anti-TNF) inhibitor?

- Yes. Please list the drug name, dates/duration of trials and outcomes in Section IX below.*
 No. Please explain why not. _____

Section VII. Please also complete for treatment of cytokine release syndrome with Actemra IV.

Please provide anticipated date of administration with concurrent CAR T-cell therapy.

Date _____

Section VIII. Please also complete for Olumiant requests.

1. Has the member tried a biologic DMARD?

Yes. Please list the drug name, dates/duration of trials and outcomes in Section IX below.*

No. Please explain why not. _____

2. Has the member tried Xeljanz or Xeljanz XR?

Yes. Please list the drug name, dates/duration of trials and outcomes in Section IX below.*

No. Please explain why not. _____

Section IX. Please complete for all requests as needed.

Please provide the following information regarding previous trials.*

Drug name/Therapy _____ Dates/duration of use _____

Did the member experience any of the following? Adverse reaction Inadequate response

Briefly describe details of adverse reaction or inadequate response.

Drug name/Therapy _____ Dates/duration of use _____

Did the member experience any of the following? Adverse reaction Inadequate response

Briefly describe details of adverse reaction or inadequate response.

Drug name/Therapy _____ Dates/duration of use _____

Did the member experience any of the following? Adverse reaction Inadequate response

Briefly describe details of adverse reaction or inadequate response.

Drug name/Therapy _____ Dates/duration of use _____

Did the member experience any of the following? Adverse reaction Inadequate response

Briefly describe details of adverse reaction or inadequate response.

Drug name/Therapy _____ Dates/duration of use _____

Did the member experience any of the following? Adverse reaction Inadequate response

Briefly describe details of adverse reaction or inadequate response.

* Please attach a letter documenting additional trials as necessary.

Section X. Please complete for requests for quantities above quantity limits.

Please describe the clinical rationale for exceeding the quantity limit.

Section XI. Please complete for all requests for non-preferred drug products if one or more preferred drug products have been designated for this class of drugs.

If one or more preferred drug products have been designated for this class of drugs, and if you are requesting PA for a non-preferred drug product, please provide medical necessity for prescribing the non-preferred drug product rather than the preferred drug product.

Prescriber information

Last name* _____ First name* _____ MI _____
NPI* _____ Individual MH Provider ID _____
DEA No. _____ Office Contact Name _____
Address _____ City _____ State _____ Zip _____
E-mail address _____
Telephone No.* _____ Fax No.* _____

* *Required*

Prescribing provider's attestation, signature, and date

I certify under the pains and penalties of perjury that I am the prescribing provider identified in the Prescriber information section of this form. Any attached statement on my letterhead has been reviewed and signed by me. I certify that the medical necessity information (per 130 CMR 450.204) on this form is true, accurate, and complete, to the best of my knowledge. I understand that I may be subject to civil penalties or criminal prosecution for any falsification, omission, or concealment of any material fact contained herein.

Prescribing provider's signature (Signature and date stamps, or the signature of anyone other than the provider, are not acceptable.)

Signature required _____

Printed name of prescribing provider _____ Date _____